Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Results of Operations
EW logo

Edwards Lifesciences Reports 15% Q3 Sales Growth Driven by TAVR Innovations

EW10-QFiling Date: 11/6/2025
Edwards Lifesciences Corporation
Description

What this story covers

Edwards Lifesciences saw 15% Q3 sales growth to $1.55B, led by TAVR and TMTT surges. Strategic divestitures and R&D investments continue. Margins held steady, but litigation and taxes pressured net income. Strong liquidity supports innovation focus.

Story snapshot

CompanyEdwards Lifesciences Corporation
TickerEW
VariantStandard detailed
Duration12:06
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001099800-25-000062

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in